Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

Presentation TCT 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presenter: Jeffrey W. Moses

October 15, 2020

Presentation TVT 2019

Cerebral Embolic Protection for TAVR With TriGuard 3: Updates From the REFLECT Clinical Trial

Presenter: Tamim Nazif

June 13, 2019

Presentation TCT 2018

Early Experiences with the New TriGUARD 3 Embolic Protection Device During TAVR: The REFLECT Trial

Presenter: Tamim Nazif

September 21, 2018

Presentation TCT 2017

Updates From the U.S. REFLECT Clinical Trial

Presenter: Tamim Nazif

October 31, 2017

Presentation TVT 2017

A Description of the U.S. REFLECT Randomized Clinical Trial

Presenter: Jeffrey W. Moses

June 15, 2017

Presentation TCT 2016

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Presenter: Helene Eltchaninoff, Neal S. Kleiman, Andreas Baumbach

November 01, 2016

Presentation TCT 2016

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Presenter: Farrell O. Mendelsohn, Stephen G. Worthley, Justin E. Davies

October 30, 2016

Presentation TCT 2014

Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients?

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Sanjay Kaul

September 15, 2014

Advertisement

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Cerebral Embolic Protection for TAVR With TriGuard 3: Updates From the REFLECT Clinical Trial

Early Experiences with the New TriGUARD 3 Embolic Protection Device During TAVR: The REFLECT Trial

Updates From the U.S. REFLECT Clinical Trial

A Description of the U.S. REFLECT Randomized Clinical Trial

Cerebral Embolic Protection II: The Keystone Deflector - Design Features and Updates From Deflect III and Reflect Clinical Trials

Assessment and Critical Appraisal of Ongoing RDN Studies: Will the Results Accurately Reflect RDN Effectiveness?

Reflections on Incorporating Vorapaxar in Contemporary Practice: Who Are the Right Patients?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content